A Cross-Sectional Observational Study to Establish the Association Between ECOG Performance Status and Age and Administration of Doublet or Triplet Chemotherapy Containing Xeloda® (capecitabine) in Advanced Gastric Cancer Patients. Eur J Oncol 2014, 18 (4), 173-180.